联合免疫,安全可行——评区域MSLN CAR-T细胞联合抗PD-1药物在治疗恶性胸膜疾病患者中的应用

    Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab

    /

    返回文章
    返回